Payment overview · 2025
General Payments
$819.75
40 reported records · 20 companies
Healthcare provider profile · identity verified
Bruce Frank Weber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GILLESPIE, IL · NPI 1609870591
Verified facts
What the public records show
CMS Open Payments records show Bruce Frank Weber, M.D. received $819.75 in general payments during 2025 across 40 reported records.
Insulet Corporation accounted for 11.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1120 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $92.46 | 11.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.97 | 8.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.50 | 8.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.03 | 7.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.37 | 7.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.42 | 6.3% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.91 | 5.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.94 | 5.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $43.94 | 5.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.00 | 5.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.74 | 5.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.23 | 4.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.18 | 3.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.50 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.71 | 2.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.76 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.62 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.11 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.45 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.91 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $819.75 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $103.97 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $92.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.97 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.50 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.03 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $57.85 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.37 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.42 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $47.91 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $39.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1120 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 165 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 85 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
267 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1120 | 114 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
230 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
165 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
165 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1120 | 114 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1907 | 356 |
| Lisinopril | Lisinopril | 1312 | 263 |
| Furosemide | Furosemide | 1231 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1229 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 1212 | 231 |
| Eliquis | Apixaban | 1120 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 913 | 183 |
| Potassium Chloride | Potassium Chloride | 884 | 141 |
| Gabapentin | Gabapentin | 784 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 700 | 157 |
| Sertraline Hcl | Sertraline Hcl | 671 | 104 |
| Trazodone Hcl | Trazodone Hcl | 612 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 598 | 104 |
| Losartan Potassium | Losartan Potassium | 595 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 566 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 514 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 510 | 105 |
| Donepezil Hcl | Donepezil Hcl | 451 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 448 | 79 |
| Citalopram Hbr | Citalopram Hydrobromide | 416 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 408 | 89 |
| Metformin Hcl | Metformin Hcl | 398 | 82 |
| Omeprazole | Omeprazole | 397 | 101 |
| Allopurinol | Allopurinol | 374 | 65 |
| Carvedilol | Carvedilol | 372 | 77 |
| Buspirone Hcl | Buspirone Hcl | 366 | 50 |
| Metformin Hcl Er | Metformin Hcl | 362 | 76 |
| Meloxicam | Meloxicam | 360 | 72 |
| Lorazepam | Lorazepam | 354 | 80 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 341 | 40 |
| Tramadol Hcl | Tramadol Hcl | 332 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 320 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 320 | 48 |
| Simvastatin | Simvastatin | 311 | 62 |
| Warfarin Sodium | Warfarin Sodium | 310 | 34 |
| Montelukast Sodium | Montelukast Sodium | 289 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 285 | 46 |
| Myrbetriq | Mirabegron | 267 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 257 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 256 | 42 |
| Famotidine | Famotidine | 245 | 65 |
| Xarelto | Rivaroxaban | 230 | 21 |
| Mirtazapine | Mirtazapine | 228 | 35 |
| Levetiracetam | Levetiracetam | 213 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 212 | 39 |
| Divalproex Sodium | Divalproex Sodium | 202 | 27 |
| Memantine Hcl | Memantine Hcl | 191 | 31 |
| Lovastatin | Lovastatin | 185 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 181 | 28 |
| Levofloxacin | Levofloxacin | 179 | 105 |
| Jardiance | Empagliflozin | 177 | 18 |
| Spironolactone | Spironolactone | 168 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 167 | 27 |
| Rexulti | Brexpiprazole | 165 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 51 |
| Januvia | Sitagliptin Phosphate | 159 | 19 |
| Prednisone | Prednisone | 152 | 56 |
| Alprazolam | Alprazolam | 150 | 23 |
| Enalapril Maleate | Enalapril Maleate | 142 | 31 |
| Ezetimibe | Ezetimibe | 138 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 35 |
| Alendronate Sodium | Alendronate Sodium | 134 | 31 |
| Atenolol | Atenolol | 134 | 32 |
| Baclofen | Baclofen | 132 | 21 |
| Glipizide | Glipizide | 132 | 22 |
| Ozempic | Semaglutide | 130 | 20 |
| Lamotrigine | Lamotrigine | 124 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 123 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 21 |
| Torsemide | Torsemide | 118 | 20 |
| Aripiprazole | Aripiprazole | 117 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 84 |
| Latanoprost | Latanoprost | 115 | 24 |
| Bupropion Xl | Bupropion Hcl | 113 | 18 |
| Finasteride | Finasteride | 111 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | 14 |
| Glipizide Er | Glipizide | 106 | 26 |
| Olanzapine | Olanzapine | 106 | 16 |
| Cephalexin | Cephalexin | 104 | 62 |
| Clonidine Hcl | Clonidine Hcl | 103 | 20 |
| Entresto | Sacubitril/Valsartan | 95 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 25 |
| Sucralfate | Sucralfate | 94 | 16 |
| Haloperidol | Haloperidol | 91 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 89 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 13 |
| Bumetanide | Bumetanide | 81 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 16 |
| Clonazepam | Clonazepam | 78 | 13 |
| Farxiga | Dapagliflozin Propanediol | 74 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 18 |
| Novolog Flexpen | Insulin Aspart | 71 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 70 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 70 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 42 |
| Rybelsus | Semaglutide | 67 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 66 | 15 |
| Lacosamide | Lacosamide | 66 | 13 |
| Nifedipine Er | Nifedipine | 66 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 64 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 12 |
| Fiasp | Insulin Aspart (Niacinamide) | 62 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 23 |
| Pregabalin | Pregabalin | 62 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 14 |
| Humalog | Insulin Lispro | 60 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | suppressed |
| Tradjenta | Linagliptin | 59 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 26 |
| Santyl | Collagenase Clostridium Hist. | 58 | 19 |
| Amoxicillin | Amoxicillin | 56 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 55 | 16 |
| Nystatin | Nystatin | 55 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 52 | 17 |
| Chlorthalidone | Chlorthalidone | 51 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 51 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 13 |
| Primidone | Primidone | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 36 |
| Digoxin | Digoxin | 48 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 23 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 44 | suppressed |
| Valsartan | Valsartan | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 13 |
| Cyclosporine | Cyclosporine | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Scopolamine | Scopolamine | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 13 |
| Topiramate | Topiramate | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 11 |
| Mirabegron Er | Mirabegron | 40 | 16 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 39 | 17 |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 25 |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Carbamazepine Er | Carbamazepine | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Clozapine | Clozapine | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 14 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Nystop | Nystatin | 31 | 21 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 28 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | 14 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 14 |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Glucagon Emergency Kit | Glucagon | 24 | 12 |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Hydroxyurea | Hydroxyurea | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Rytary | Carbidopa/Levodopa | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 14 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $819.75 · 40 records | Insulet Corporation | BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, Korlym, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, RECORLEV, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error